Normal
'Market Matters' Friday afternoon reportNot HeldResMed (RMD) +5.92% reported after hours in the US with revenue of $1.22bn up 11% YoY and ahead of $1.19bn expected, EPS of $2.20 vs $2.07 consensus. Commentary was strong, the CEO Mick Farrell saying “Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business.”
'Market Matters' Friday afternoon report
Not Held
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.